Cover Image
市場調查報告書

核因子kappa B激酶次單元β抑制劑:開發中產品分析

Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 408759
出版日期 內容資訊 英文 38 Pages
訂單完成後即時交付
價格
Back to Top
核因子kappa B激酶次單元β抑制劑:開發中產品分析 Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) - Pipeline Review, H2 2017
出版日期: 2017年08月29日 內容資訊: 英文 38 Pages
簡介

本報告提供以核因子kappa B激酶次單元β抑制劑為標的治療藥之開發平台現狀及最新更新的各開發階段比較分析,提供你涵括最新的新聞和發表之企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

核因子kappa B激酶次單元β抑制劑 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • 第一三共
  • EntreChem, S.L.
  • IMMD Inc.

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0992TDB

Summary:

According to the recently published report 'Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta - Pipeline Review, H2 2017'; Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) pipeline Target constitutes close to 7 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes.

Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) - Inhibitor of nuclear factor kappa-B kinase subunit beta is a protein encoded by the IKBKB gene. It plays an essential role in the NF-kappa-B signaling pathway which is activated by multiple stimuli such as inflammatory cytokines, bacterial or viral products, DNA damages or other cellular stresses. It acts as part of the canonical IKK complex in the conventional pathway of NF-kappa-B activation and phosphorylates inhibitors of NF-kappa-B on 2 critical serine residues. Free NF-kappa-B is translocated into the nucleus and activates the transcription of hundreds of genes involved in immune response, growth control, or protection against apoptosis.

The report 'Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta - Pipeline Review, H2 2017' outlays comprehensive information on the Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Preclinical stages are 5 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology and Gastrointestinal which include indications Glioblastoma Multiforme (GBM), Inflammation, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Breast Cancer, Colorectal Cancer, Inflammatory Bowel Disease, Mantle Cell Lymphoma, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Rheumatoid Arthritis and Solid Tumor.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10)
  • The report reviews Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) - Overview
    • Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) - Companies Involved in Therapeutics Development
    • Daiichi Sankyo Company Ltd
    • EntreChem SL
    • IMMD Inc
  • Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) - Drug Profiles
    • 13-197 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EC-70124 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IMD-0560 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit I-KappaB Kinase Beta for Rheumatoid Arthritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit IKK-B for Inflammation and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit IKKb for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TLX-1423 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) - Dormant Products
  • Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) - Discontinued Products
  • Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) - Product Development Milestones
    • Featured News & Press Releases
      • Mar 10, 2016: EntreChem's orally active EC-70124 reverts tumorigenic and stem cell properties in prostate cancer
      • Dec 21, 2015: New EntreChem publication in Oncotarget describing activity of EC-70124 in colorectal cancer
      • Sep 26, 2014: EntreChem presents in ESMO 2014 congress: Activity of the multi-targeted kinase inhibitor EC-70124 in colorectal cancer
      • Jun 02, 2014: EntreChem presents in 2014 ASCO Annual Meeting: Activity of the multi-targeted kinase inhibitor EC-70124 in Triple Negative Breast Cancer
      • Apr 30, 2013: Entrechem Announces Presentation Of Positive Preclinical Results Of Orally Active Kinase Inhibitor EC-70124 At 2013 AACR Annual Meeting
      • Mar 26, 2012: EntreChem's Kinase Inhibitor Shows Potential For Treatment Of Head And Neck Cancer
      • May 09, 2011: EntreChem's Developmental Drug EC-70124 Creates New Strategy For Treatment Of Glioblastoma
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indication, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products under Investigation by Universities/Institutes, H2 2017
  • Products under Investigation by Universities/Institutes, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by Daiichi Sankyo Company Ltd, H2 2017
  • Pipeline by EntreChem SL, H2 2017
  • Pipeline by IMMD Inc, H2 2017
  • Dormant Products, H2 2017
  • Dormant Products, H2 2017 (Contd..1), H2 2017
  • Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top